Several systematic reviews and meta-analyses have assessed the outcomes of PD-1/PD-L1 inhibitors or specific immune combinations in ovarian cancer, reporting modest improvements in PFS or ORR but increased toxicity profiles (14, 15). This evidence concerns the gene PDCD1 and ovarian carcinoma.